Danish study of 92 355 adults compared Fx rates between new users of denosumab (DEN) or alendronate - finds no advantage for DEN for hip Fx (aHR 1.08; 0.92-1.28) or any Fx (aHR 0.92; 0.83-1.02). Data doesnt support preference for DEN in high risk pts. https://t.co/dpyRF9VxH6